188 related articles for article (PubMed ID: 33505698)
1. Clinical complications in patients with primary and recurrent
Feuerstadt P; Boules M; Stong L; Dahdal DN; Sacks NC; Lang K; Nelson WW
SAGE Open Med; 2021; 9():2050312120986733. PubMed ID: 33505698
[TBL] [Abstract][Full Text] [Related]
2. Healthcare resource utilization and direct medical costs associated with index and recurrent
Feuerstadt P; Stong L; Dahdal DN; Sacks N; Lang K; Nelson WW
J Med Econ; 2020 Jun; 23(6):603-609. PubMed ID: 31999199
[No Abstract] [Full Text] [Related]
3. Health care resource utilization and costs of recurrent
Nelson WW; Scott TA; Boules M; Teigland C; Parente A; Unni S; Feuerstadt P
J Manag Care Spec Pharm; 2021 Jul; 27(7):828-838. PubMed ID: 33703939
[No Abstract] [Full Text] [Related]
4. Clinical burden of recurrent
Feuerstadt P; Nelson WW; Teigland C; Dahdal DN
Antimicrob Steward Healthc Epidemiol; 2022; 2(1):e60. PubMed ID: 36483433
[TBL] [Abstract][Full Text] [Related]
5. Epidemiological and clinical burden of Clostridioides difficile infections and recurrences between 2015 - 2019: the RECUR Germany study.
Tricotel A; Antunes A; Wilk A; Dombrowski S; Rinta-Kokko H; Andersson FL; Ghosh S
BMC Infect Dis; 2024 Mar; 24(1):357. PubMed ID: 38539166
[TBL] [Abstract][Full Text] [Related]
6. Mortality, Health Care Use, and Costs of Clostridioides difficile Infections in Older Adults.
Feuerstadt P; Nelson WW; Drozd EM; Dreyfus J; Dahdal DN; Wong AC; Mohammadi I; Teigland C; Amin A
J Am Med Dir Assoc; 2022 Oct; 23(10):1721-1728.e19. PubMed ID: 35288083
[TBL] [Abstract][Full Text] [Related]
7. Mortality, healthcare resource utilization, and cost among Medicare beneficiaries with
Amin A; Nelson WW; Dreyfus J; Wong AC; Mohammadi I; Teigland C; Dahdal DN; Feuerstadt P
Ther Adv Infect Dis; 2022; 9():20499361221095679. PubMed ID: 35510091
[TBL] [Abstract][Full Text] [Related]
8. Surgical Infection Society Guidelines for Total Abdominal Colectomy versus Diverting Loop Ileostomy with Antegrade Intra-Colonic Lavage for the Surgical Management of Severe or Fulminant, Non-Perforated
Forrester JD; Colling KP; Diaz JJ; Faliks B; Kim PK; Tessier JM; Tung J; Huston JM
Surg Infect (Larchmt); 2022 Mar; 23(2):97-104. PubMed ID: 34619068
[No Abstract] [Full Text] [Related]
9. Economic burden of recurrent Clostridioides difficile infection in adults admitted to Spanish hospitals. A multicentre retrospective observational study.
Bouza E; Cobo J; Rodríguez-Hernández MJ; Salavert M; Horcajada JP; Iribarren JA; Obi E; Lozano V; Maratia S; Cuesta M; Uría E; Limón E
Rev Esp Quimioter; 2021 Apr; 34(2):126-135. PubMed ID: 33618513
[TBL] [Abstract][Full Text] [Related]
10. Healthcare burden of recurrent Clostridioides difficile infection in Japan: A retrospective database study.
Kunishima H; Ito K; Laurent T; Abe M
J Infect Chemother; 2018 Nov; 24(11):892-901. PubMed ID: 30190105
[TBL] [Abstract][Full Text] [Related]
11. Characterization and risk factors for recurrence of Clostridioides (Clostridium) difficile infection in Japan: A nationwide real-world analysis using a large hospital-based administrative dataset.
Kimura T; Snijder R; Sugitani T
J Infect Chemother; 2019 Aug; 25(8):615-620. PubMed ID: 30987950
[TBL] [Abstract][Full Text] [Related]
12. Economic Impact of Recurrent Clostridioides difficile Infection in the USA: A Systematic Literature Review and Cost Synthesis.
Reveles KR; Yang M; Garcia-Horton V; Edwards ML; Guo A; Lodise T; Bochan M; Tillotson G; Dubberke ER
Adv Ther; 2023 Jul; 40(7):3104-3134. PubMed ID: 37210680
[TBL] [Abstract][Full Text] [Related]
13. Predictors and burden of hospital readmission with recurrent Clostridioides difficile infection: a French nation-wide inception cohort study.
Dinh A; Le Monnier A; Emery C; Alami S; Torreton É; Duburcq A; Barbier F
Eur J Clin Microbiol Infect Dis; 2019 Jul; 38(7):1297-1305. PubMed ID: 30941532
[TBL] [Abstract][Full Text] [Related]
14. An Observational Cohort Study of
Rao K; Higgins PDR; Young VB
mSphere; 2018; 3(3):. PubMed ID: 29794054
[TBL] [Abstract][Full Text] [Related]
15. Real-World Experience with Bezlotoxumab for Prevention of Recurrence of
Escudero-Sánchez R; Ruíz-Ruizgómez M; Fernández-Fradejas J; García Fernández S; Olmedo Samperio M; Cano Yuste A; Valencia Alijo A; Díaz-Pollán B; Rodríguez Hernández MJ; Merino De Lucas E; Martín Segarra O; Sáez Bejar C; Armiñanzas Castillo C; Gutiérrez Gutiérrez B; Rodríguez-Pardo D; Ramos Martínez A; De La Torre Cisneros J; López-Medrano F; Cobo Reinoso J
J Clin Med; 2020 Dec; 10(1):. PubMed ID: 33374989
[TBL] [Abstract][Full Text] [Related]
16. Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials.
Madoff SE; Urquiaga M; Alonso CD; Kelly CP
Anaerobe; 2020 Feb; 61():102098. PubMed ID: 31493500
[TBL] [Abstract][Full Text] [Related]
17. Incidence of and risk factors for recurrent Clostridioidesdifficile infection in Japan using a claims database: A retrospective cohort study.
Mikamo H; Kondo T; Okuyama K; Marcella SW; Ruzicka DJ
Anaerobe; 2020 Feb; 61():102139. PubMed ID: 31830597
[TBL] [Abstract][Full Text] [Related]
18. Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI.
Finn E; Andersson FL; Madin-Warburton M
BMC Infect Dis; 2021 May; 21(1):456. PubMed ID: 34016040
[TBL] [Abstract][Full Text] [Related]
19. Real-world Experience of Bezlotoxumab for Prevention of
Hengel RL; Ritter TE; Nathan RV; Van Anglen LJ; Schroeder CP; Dillon RJ; Marcella SW; Garey KW
Open Forum Infect Dis; 2020 Apr; 7(4):ofaa097. PubMed ID: 32363211
[TBL] [Abstract][Full Text] [Related]
20. RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients' Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections.
Khanna S; Pardi DS; Jones C; Shannon WD; Gonzalez C; Blount K
Clin Infect Dis; 2021 Oct; 73(7):e1613-e1620. PubMed ID: 32966574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
